News and Updates

Current News

12/17/2024: Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

12/17/2024: Hepatitis D Virus Status Among People With Hepatitis B Virus Infection: A Disconnect Between Guidelines and Practice

12/09/2024: Improving Hepatitis D Screening in Patients With Chronic HBV

11/2024: Hepatitis Delta Coinfection Rates and All-Cause Mortality Among Hepatitis B-Infected Veterans in the USA

11/21/2024: Hepatitis B and D virus entry

11/20/2024: VIDEO: Combination tobevibart, elebsiran induces ‘rapid virologic suppression’ in HDV

11/2024: CURRENT AND FUTURE THERAPEUTIC OPTIONS FOR CHRONIC HEPATITIS D VIRUS INFECTION

11/19/2024: Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

11/18/2024: Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

11/18/2024: FDA Grants Breakthrough Therapy Designation to Huahui Health’s Libevitug (HH-003) for treatment of chronic Hepatitis D virus infection

11/15/2024: Investigational Hepatitis D Monoclonal Antibody Achieves 100% Virologic Response

11/12/2024:  ‘Change the HDV narrative’: A call to heighten awareness, prioritize early detection

11/2024: The Changing Face of Hepatitis Delta Virus Associated Hepatocellular Carcinoma

10/20/2024: Poor Hepatitis D Screening in HBV Patients Impacts Survival Outcomes

9/29/2024: Standardized Surveillance Case Definition for Hepatitis D Virus (HDV) Infection

9/29/2024: Availability of point-of-care HBV tests in resource-limited settings

8/14/2024: Assessing the diagnostic accuracy of serological tests for hepatitis delta virus diagnosis: a systematic review and meta-analysis

8/6/2024: The Prevalence and Molecular Epidemiology of Hepatitis Delta Virus in Nigeria: The Results of a Nationwide Study

7/30/2024: Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the Phase III MYR301 trial of bulevirtide

7/23/2024: Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection

7/22/2024: Pharmacists Boost Hepatitis D Treatment Success with Hands-On Education

7/1/2024: Drs Alan Bonder and Robert Gish Discuss Screening and Treatment for Hepatitis D

6/18/2024: Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024

6/18/2024: Tobevibart, elebsiran can suppress hepatitis D virus: Phase 2 data

6/18/2024: Bulevirtide Plus Pegylated Interferon Can Maintain Undetectable Hepatitis D

6/18/2024: Video: Bulevirtide remains ‘efficacious, well tolerated’ in chronic hepatitis D at 2 years

6/18/2024: BJT-778 antibody therapy shows early promise in Hep D trial

6/12/2024: A changing landscape: Tracking and analysis of the international HDV epidemiology 1999–2020

5/15/2024: Protective role of RIPK1 scaffolding against HDV-induced hepatocyte cell death and the significance of cytokines in mice

5/13/2024: Innovating for a Healthier Tomorrow: Ribocure’s Role in Transforming Liver Disease Treatment with siRNA

5/6/2024: Impact of anti-HDV reflex testing at HBs antigen positive discovery in a single center France: Support for primary HDV screening in France

3/25/2024: Bluejay Announces Receipt of PRIME Designation from European Medicines Agency (EMA) for BJT-778 for the Treatment of Chronic Hepatitis Delta Virus Infection

3/11/2024: Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta

3/8/2024: Growing Awareness: Limited Testing and Screening Bias for Hepatitis Delta Virus in Utah 2000–2021

3/5/2024: Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule

2/14/2024: Eliminating viral hepatitis: no room for complacency

News Archive

12/19/2023: Prevalence of hepatitis D virus infection among patients with chronic hepatitis B infection in a tertiary care centre in Thailand

11/29/2023: Transient elastography effectively detects severe fibrosis, cirrhosis in HDV

11/17/2023: Prevalence and characteristics of hepatitis delta virus infection in patients with hepatitis B in the United States: An analysis of the All-Payer Claims Database

11/14/2023: Replicor updates REP 2139-Mg compassionate use and mechanistic data at AASLD 2023

11/9/2023: Hepatitis D: A Review

11/2023: Maternal-to-Child Transmission of Hepatitis B Virus and Hepatitis Delta Virus

11/2023: Hepatitis D: a neglected aspect of elimination efforts

10/25/2023: Comparative effectiveness of seven interventions for chronic hepatitis D: a systematic review and network meta-analysis of randomized controlled trials

10/03/2023: The elimination of hepatitis D as a public health problem: Needs and challenges

10/03/2023: AB-1659, A Potent Orally Bioavailable NTCP Inhibitor That Blocks Entry of HBV/HDV Viruses

10/02/2023: Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor

09/12/2023: Late-Stage Trial in Chronic Hepatitis D Discontinued Due to Safety Concerns

08/14/2023: Prevalence and genotypes distribution of virus hepatitis B and hepatitis delta virus in chronic liver diseases in Kazakhstan

08/12/2023: An Insight Into the Factors Affecting the Prevalence and Natural History of Hepatitis D

08/07/2023: A promising investigational therapeutic monoclonal antibody to treat chronic hepatitis B and D infections

07/28/2023: New Study Dismantles Everything We Knew About The Disease

07/26/2023: Diagnosis and Management of Hepatitis Delta Virus Infection

07/26/2023: Development of quantitative multiplex RT-qPCR one step assay for detection of hepatitis delta virus

07/24/2023: Prevalence and determinants of hepatitis delta virus infection among HIV/hepatitis B-coinfected adults in care in the United States

07/06/2023: A Glimmer of Hope for an Orphan Disease

07/06/2023: Hepatitis D Virus Infection

07/06/2023: A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D

06/29/2023: Lonafarnib regimens ‘exceed end-of-treatment response’; oral therapy may be viable in HDV

06/28/2023: Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022

06/24/2023: Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D

06/23/2023: Gilead reports positive results in HDV patients previously unresponsive to therapy

06/23/2023: Gilead data reinforce case for Hepcludex in hepatitis delta

06/23/2023: EASL Clinical Practice Guidelines on hepatitis delta virus

06/22/2023: Advancing research, awareness, screening, and linkage to care to eliminate HDV in the U.S.

06/21/2023: Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference

06/21/2023: Significantly Higher Clinical and Economic Burden Following Diagnosis of Hepatitis Delta Virus Infection Among Commercially Insured Adults With Chronic Hepatitis B in the United States

06/14/2023: Hepatitis Delta Virus Infection in the United States: If You Seek, You May Find

06/01/2023: Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial Enrollment

05/17/2023: The Many Functions Of The Hepatitis D Antigen Proteins

05/16/2023: Hundreds of NHS patients in England and Wales offered access to first treatment conditionally licensed for the most aggressive form of viral hepatitis

05/15/2023: With NICE nod, Gilead clears another regulatory hurdle in Europe for Hepcludex

05/10/2023: RNA Gymnastics: How Does Hepatitis Delta Virus Replicate?

05/05/2023: After FDA rejection, Gilead's Hepcludex looks set for full EU nod

04/07/2023: Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression

04/06/2023: Molecular and Clinical Features of Hepatocellular Carcinoma in Patients with HBV-HDV Infection

04/06/2023: Hepatitis D double reflex testing of all hepatitis B carriers in low HBV and high HBV/high HDV prevalence countries

03/20/2023: Real-world studies show efficacy, safety of BLV monotherapy in patients with HDV-related compensated cirrhosis

03/17/2023: Hepatitis Delta, Aisf and Simit specialists present joint and updated document

03/14/2023: Scottish Medicines Consortium accepts treatment for chronic hepatitis delta virus

03/2023: Improved hepatitis delta virus genome characterization by single molecule full-length genome sequencing combined with VIRiONT pipeline

01/21/2023: Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy

01/11/2023: Identifying and Screening At-Risk Patients for Hepatitis Delta Virus: A Case Report

01/03/2023: A 3-Year Course Of Bulevirtide Monotherapy May Cure HDV Infection In Cirrhotics

01/2023: Effect of variants in LGP2 on MDA5-mediated activation of interferon response and suppression of hepatitis D virus replication

12/2022: Low Performance of Hepatitis Delta Virus Testing Among 2 National Cohorts of Chronic Hepatitis B Patients in the United States

12/8/2022: Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint

11/26/2022: The Delta Delta: Gaps in screening and patient assessment for hepatitis D virus infection

11/11/2022: Bulevirtide Improves Health-Related Quality of Life (Phase 3 Clinical Trial Presentation at AASLD)

11/04/2022: Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV

10/27/2022: Gilead Receives Complete Response Letter from U.S. FDA for Bulevirtide for the Treatment of Adults with Hepatitis Delta Virus.

10/27/2022: COVID-19 Impacts HDV Screening, Patient Outcomes

10/17/2022: Identification of a novel interaction site between the large hepatitis delta antigen and clathrin that regulates the assembly of genotype III hepatitis delta virus

09/2022: Presentation from International HBV Meeting: Combined results from the clinical trials MYR203 and MYR301, in patients with chronic hepatitis D

02/17/2022: Four Questions with Professor Maria Buti: Understanding Hepatitis D

02/11/2022: New Hepatitis Delta Podcast Episode: Viral Hepatitis: On the Road to Elimination

02/04/2022: Patient Perspective: Living with HBV and HDV Coinfection in Pandemic Times

01/20/2022: Hepatitis D Changing Context Global Prevalence

01/04/2022: New Slideset Updated on Don't Delay with Delta: Best Practices and Calls to Action in HDV

12/21/2021: Bulevirtide Improves Quality of Life in Chronic HDV

12/21/2021: Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection

12/20/2021: Medical Minutes Podcasts on HDV Epidemiology and Universal Screening

12/16/2021: UN Adopts Resolution on Rare Diseases

12/13/2021: Bulevirtide Shows Real-World Efficacy Versus HDV

12/03/2021: Should We Screen All Patients with Hepatitis B for Hepatitis Delta?

12/01/2021: Hepatitis Delta Presentations from the 2021 AASLD Liver Meeting Now Available

12/01/2021: Ethnic Variations in Clinical Presentation and Treatment Eligibility for HDV Infection at a US Referral Center

11/19/2021: Gilead Files BLA for Bulevirtide to Treat Chronic HDV Infection

11/12/2021: Prevalence and Characteristics of Hepatitis Delta in the United States: An Analysis of All-Payer Claims Databases

09/29/2021: The Kinesin KIF4 Mediates HBV/HDV Entry Through Regulation of Surface NTCP Localization and Can Be Targeted by RXR Agonists in vitro

08/24/2021: The Highly Complementary Model of Hepatitis D and Hepatitis B, Described by Scientists, Can Broadly Cover the HDV Replication Cycle

07/28/2021: Hepatitis D: Neglected Disease in the Race to Eliminate Viral Hepatitis by 2030

07/27/2021: Risk of Hepatocellular Carcinoma in Hepatitis B & D Virus Co-Infected Patients: A Systematic Review and Meta-Analysis of Longitudinal Studies

07/12/2021: Significant Disruptions in the International Incidence of Hepatitis Delta Virus

06/25/2021: Gilead Preps Filing for Hepatitis D Therapy Hepcludex in US

06/24/2021: Treatment With Hepcludex® (Bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 Weeks

04/01/2021: Hepatitis Delta Infection Among Persons with HIV in Europe

11/30/2020: New Insights into Hepatitis D Virus Persistence: The Role of Interferon Response and Implications for Upcoming Novel Therapies

11/17/2020: Eiger Announces Positive Peginterferon Lambda-Lonafarnib Combination End-of-Study Results from Phase 2 LIFT HDV Study at the Liver Meeting Digital Experience 2020

11/16/2020: Eiger Announces Case Studies Demonstrating Regression of Liver Fibrosis Following 48 Weeks of Therapy with Peginterferon Lambda in Patients with Chronic HDV Infection at the Liver Meeting Digital Experience 2020

10/7/2020: Risk Factors for Delta Hepatitis in a North American Cohort: Who Should Be Screened? 

9/17/2020: Hepcludex Launched in Germany, France, and Austria

8/31/2020: End of Treatment Results Presented for Lambda-Interferon + Lonafarnib Combination Phase 2 LIFT Study at International Liver Congress, 2020

8/5/2020: Hepcludex Approved by European Commission

6/2/2020: MYR Pharmaceuticals Receives Positive Opinion from EMA for Hepcludex for the Treatment of Chronic Hepatitis Delta

2/18/2020: New Insights into Hepatitis B and Hepatitis Delta Virus Entry

2/1/2020: The Effect of Twelve Weeks of Treatment with Ezetimibe on HDV RNA Level in Patients with Chronic Hepatitis D

1/2/2020: Hepatitis Delta Has Higher Health Care Cost Burden Than Hepatitis B

1/2020: The epidemiology of hepatitis delta virus infection in Cameroon

12/26/2019: REP2139 Demonstrates Functional Cure in Both HBV, HDV 

11/12/2019: Eiger Announces Phase 2 LIFT Study Results During AASLD 2019

11/1/2019: MYR Pharmaceuticals to Present on Myrcludex B During AASLD 2019

11/1/2019: FDA Guidance to Help with Hepatitis Delta Drug Development

8/20/2019: Pegylated Interferon Lambda Receives FDA Breakthrough Therapy Designation

7/29/2019: Russia Plans Production of Myrcludex B

4/13/2019: MYR Announces Phase 2 Myrcludex B Trial Data at The International Liver Congress 2019

4/11/2019: Eiger Announces Phase 2 LIMT Hepatitis Delta Study Progress at The International Liver Congress 2019

3/5/2019: MYR Pharma Announces Grant of Promising Innovative Medicine (PIM) Designation by British MHRA for Myrcludex B

12/18/2018: Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib

12/17/2018: Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib

6/4/2018: Digestive Disease Week: Hepatitis Delta: The 'Forgotten Virus' is Still Here

10/23/2018: MYR Pharma Announces FDA Breakthrough Therapy Designation for Myrcludex B

9/5/2017:  Pegylated Interferon Lambda Receives FDA Orphan Drug Designation

7/27/2017: Pegylated Interferon Lambda Receives FDA Fast Track Designation 

5/25/2017: MYR Pharma Announces Myrcludex B PRIME Designation by the EMA

12/23/2014: EB Pharma Announces License Agreement for Tipifarnib from Janssen Pharmaceutica for Development in Hepatitis Delta 

12/22/2014: Lonafarnib Recieves Orphan Drug Designation by FDA and EMA